CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT02484430
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:47.401747+00:00
- Published At
- 2022-05-24T00:00:00+00:00
- Record Updated At
- 2025-03-03
- Results Posted At
- 2022-05-24
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["B Acute Lymphoblastic Leukemia", "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Recurrent Adult Acute Lymphoblastic Leukemia", "Refractory Adult Acute Lymphoblastic Leukemia", "T Acute Lymphoblastic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-03-03"- protocolSection.identificationModule.nctId
"NCT02484430"- protocolSection.identificationModule.officialTitle
"A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2022-05-24"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.